KEYNOTE-033: Phase 3 study of pembrolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (NSCLC)

被引：0
|
作者：
Zhou, C. [1 ]
Caglevic, C. [2 ]
Zhou, J. [3 ]
Wang, B. [4 ]
Wang, K. [5 ]
Ge, J. [6 ]
Zhou, Y. [6 ]
Piperdi, B. [7 ]
Ma, Z. [8 ]
机构：
[1] Shanghai Pulm Hosp, Dept Oncol, Shanghai, Peoples R China
[2] FALP, Dept Oncol, Santiago, Chile
[3] Zhejiang Univ, Hosp 1, Dept Respirat, Hangzhou, Zhejiang, Peoples R China
[4] Subei Peoples Hosp, Dept Oncol, Yangzhou, Jiangsu, Peoples R China
[5] Zhejiang Univ, Hosp 2, Dept Respirat, Hangzhou, Zhejiang, Peoples R China
[6] MSD China, Oncol, Shanghai, Peoples R China
[7] Merck & Co Inc, Oncol, Kenilworth, NJ USA
[8] Henan Canc Hosp, Dept Oncol, Zhengzhou, Henan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
466TiP
引用
收藏
页码：143 / 143
页数：1
相关论文
共 50 条
  • [1] KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC
    Ren, Shengxiang
    Feng, Jifeng
    Ma, Shenglin
    Chen, HuaJun
    Ma, Zhiyong
    Huang, Cheng
    Zhang, Li
    He, Jianxing
    Wang, Changli
    Zhou, Jianying
    Danchaivijtr, Pongwut
    Wang, Chin-Chou
    Vynnychenko, Ihor
    Wang, Kai
    Orlandi, Francisco
    Sriuranpong, Virote
    Li, Ben
    Ge, Jun
    Dang, Thao
    Zhou, Caicun
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (03) : 623 - 634
  • [2] Docetaxel for previously treated non-small-cell lung cancer
    Fossella, FV
    ONCOLOGY-NEW YORK, 2002, 16 (06): : 45 - 51
  • [3] A phase II trial of pevonedistat plus docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC)
    Wells, Leah
    Qin, Angel
    Rice, John
    Gadgeel, Shirish M.
    Schneider, Bryan J.
    Ramnath, Nithya
    Zhao, Lili
    Kalemkerian, Gregory Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Multicenter, randomized study of Docetaxel versus Docetaxel plus Oblimersen in patients previously treated for non-small cell lung cancer (NSCLC)
    Herbst, Roy S.
    Ansari, Rafat H.
    Gorbunova, V
    Manikhas, G.
    Mansoor, N. Boyd
    Thomas, E.
    Azzoli, Christopher G.
    Robert, Francisco
    Itri, Loretta M.
    Chapman, Robert
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S335 - S335
  • [5] Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
    Hanna, N
    Shepherd, FA
    Fossella, FV
    Pereira, JR
    De Marinis, F
    von Pawel, J
    Gatzemeier, U
    Tsao, TCY
    Pless, M
    Muller, T
    Lim, HL
    Desch, C
    Szondy, K
    Gervais, R
    Shaharyar
    Manegold, C
    Paul, S
    Paoletti, P
    Einhorn, L
    Bunn, PA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) : 1589 - 1597
  • [6] Phase I/II study of weekly docetaxel in patients with previously treated non-small cell lung cancer (NSCLC).
    Hirata, T
    Kawashita, F
    Ogawa, E
    Masago, K
    Kato, M
    Takada, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 676S - 676S
  • [7] A Phase II Trial of Pevonedistat and Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
    Qin, Angel
    Wells, Leah
    Malhotra, Binu
    Gadgeel, Shirish
    Schneider, Bryan J.
    Ramnath, Nithya
    Rice, John D.
    Kalemkerian, Gregory P.
    CLINICAL LUNG CANCER, 2024, 25 (02) : 128 - 134
  • [8] Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
    Kim, Edward S.
    Hirsh, Vera
    Mok, Tony
    Socinski, Mark A.
    Gervais, Radj
    Wu, Yi-Long
    Li, Long-Yun
    Watkins, Claire L.
    Sellers, Mark V.
    Lowe, Elizabeth S.
    Sun, Yan
    Liao, Mei-Lin
    Osterlind, Kell
    Reck, Martin
    Armour, Alison A.
    Shepherd, Frances A.
    Lippman, Scott M.
    Douillard, Jean-Yves
    LANCET, 2008, 372 (9652): : 1809 - 1818
  • [9] Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
    Herbst, Roy S.
    Baas, Paul
    Kim, Dong-Wan
    Felip, Enriqueta
    Perez-Gracia, Jose L.
    Han, Ji-Youn
    Molina, Julian
    Kim, Joo-Hang
    Arvis, Catherine Dubos
    Ahn, Myung-Ju
    Majem, Margarita
    Fidler, Mary J.
    de Castro, Gilberto, Jr.
    Garrido, Marcelo
    Lubiniecki, Gregory M.
    Shentu, Yue
    Im, Ellie
    Dolled-Filhart, Marisa
    Garon, Edward B.
    LANCET, 2016, 387 (10027): : 1540 - 1550
  • [10] A phase II study of oxaliplatin and docetaxel in patients with advanced non-small-cell lung cancer (NSCLC)
    Raez, L
    Santos, E
    Rocha-Lima, C
    Roman, E
    Kumar, P
    Farfan, N
    Decesare, T
    Lopes, G
    Rosado, M
    Wu, J
    LUNG CANCER, 2005, 49 : S265 - S265
12345